NO20050427L - Carvedilolfosfatsalter og/eller solvater derav, tilsvarende preparater og/eller behandlingsfremgangsmater - Google Patents
Carvedilolfosfatsalter og/eller solvater derav, tilsvarende preparater og/eller behandlingsfremgangsmaterInfo
- Publication number
- NO20050427L NO20050427L NO20050427A NO20050427A NO20050427L NO 20050427 L NO20050427 L NO 20050427L NO 20050427 A NO20050427 A NO 20050427A NO 20050427 A NO20050427 A NO 20050427A NO 20050427 L NO20050427 L NO 20050427L
- Authority
- NO
- Norway
- Prior art keywords
- solvates
- treatment methods
- phosphate salts
- corresponding preparations
- carvedilol phosphate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39217502P | 2002-06-27 | 2002-06-27 | |
PCT/US2003/020408 WO2004002419A2 (en) | 2002-06-27 | 2003-06-27 | Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20050427L true NO20050427L (no) | 2005-01-25 |
NO329710B1 NO329710B1 (no) | 2010-12-06 |
Family
ID=30000823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20050427A NO329710B1 (no) | 2002-06-27 | 2005-01-25 | Carvedilolfosfatsalter og/eller solvater derav, samt farmasoytiske preparater omfattende disse |
Country Status (15)
Country | Link |
---|---|
US (6) | US7268156B2 (no) |
EP (1) | EP1534270A4 (no) |
JP (3) | JP2005533823A (no) |
KR (3) | KR20110134952A (no) |
CN (6) | CN103333099A (no) |
AU (1) | AU2003248746B2 (no) |
BR (1) | BR0312102A (no) |
CA (1) | CA2492060C (no) |
EA (1) | EA008384B1 (no) |
IL (1) | IL165814A (no) |
MX (1) | MXPA04012923A (no) |
NO (1) | NO329710B1 (no) |
NZ (1) | NZ537161A (no) |
WO (1) | WO2004002419A2 (no) |
ZA (1) | ZA200410011B (no) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004501191A (ja) * | 2000-06-28 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | カルベジロール |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
EP1474133A4 (en) | 2002-01-15 | 2006-02-01 | Teva Pharma | SOLID CRYSTALLINE CARVEDILOL BODIES AND METHODS OF MAKING SAME |
JP2006500320A (ja) * | 2002-04-30 | 2006-01-05 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール一クエン酸塩一水和物 |
AU2003251627A1 (en) | 2002-06-27 | 2004-01-19 | Sb Pharmco Puerto Rico Inc. | Carvedilol hydrobromide |
BR0312102A (pt) * | 2002-06-27 | 2007-05-29 | Sb Pharmco Inc | sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento |
AU2003267785C1 (en) | 2002-09-13 | 2009-12-24 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
JP2007512372A (ja) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール塩、対応する組成物、送達および/または治療方法 |
WO2005051325A2 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Carvedilol compositions methods of treatment and delivery |
US8734850B2 (en) * | 2003-11-25 | 2014-05-27 | Flamel Technologies | Oral medicinal product with modified release of at least one active principle in multimicrocapsular form |
KR20070088507A (ko) * | 2005-06-09 | 2007-08-29 | 테바 파마슈티컬 인더스트리즈 리미티드 | 카베딜올의 결정질 형태 및 이것의 제조 방법 |
WO2007144900A2 (en) * | 2006-06-14 | 2007-12-21 | Matrix Laboratories Limited | Carvedilol phosphate sesquihydrate |
EP1991527A2 (en) * | 2006-06-28 | 2008-11-19 | Teva Pharmaceutical Industries Ltd | Polymorphous forms of carvedilol phosphate |
US20080292695A1 (en) * | 2006-12-01 | 2008-11-27 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
US20090028935A1 (en) * | 2006-12-01 | 2009-01-29 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
WO2008084494A1 (en) * | 2007-01-08 | 2008-07-17 | Matrix Laboratories Limited | Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same |
US20080207726A1 (en) * | 2007-02-26 | 2008-08-28 | Santiago Ini | Process for the purification of carvedilol or its salts thereof |
WO2008104990A1 (en) * | 2007-02-27 | 2008-09-04 | Lupin Limited | Amorphous carvedilol dihydrogen phosphate |
US20080249317A1 (en) * | 2007-04-04 | 2008-10-09 | Apotex Inc. | Novel amorphous form of carvedilol phosphate and processes for the preparation thereof |
WO2008142703A1 (en) * | 2007-05-17 | 2008-11-27 | Wanbury Limited | A novel cost effective process for production of carvedilol phosphate |
EP2014649A1 (en) * | 2007-06-27 | 2009-01-14 | Inke, S.A. | Novel amorphous carvedilol dihydrogen phosphate |
WO2009008009A1 (en) * | 2007-07-11 | 2009-01-15 | Lupin Limited | Novel crystalline form b of carvedilol dihydrogen phosphate |
US20100076047A1 (en) * | 2007-08-20 | 2010-03-25 | Sankar Reddy Budidet | Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt |
EP2195292B1 (en) | 2007-08-21 | 2013-10-02 | Lupin Ltd. | Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer |
US20090076283A1 (en) * | 2007-09-07 | 2009-03-19 | Scinopharm Taiwan Ltd. | Method of crystallizing carvedilol phosphate and the product thereof |
US20090111998A1 (en) * | 2007-10-25 | 2009-04-30 | Srinivas Reddy Gade | Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof |
US20110015247A1 (en) * | 2008-04-04 | 2011-01-20 | Shodhana Laboratories Limited | Novel crystalline form of carvedilol dihydrogen phosphate and related processes |
US7763645B2 (en) * | 2008-05-23 | 2010-07-27 | Wanbury Limited | Carvedilol dihydrogen phosphate monohydrate |
CN101891671B (zh) * | 2010-07-26 | 2012-06-27 | 天津大学 | 一种卡维地洛磷酸二氢盐的晶体及其制备方法 |
US8492426B1 (en) | 2012-07-12 | 2013-07-23 | Anis Ahmad | Use of carvedilol for treatment of diabetes mellitus |
CN106892858A (zh) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | 一种卡维地洛磷酸二氢盐新晶型 |
US10357476B1 (en) | 2018-10-30 | 2019-07-23 | Anis Ahmad | Method for treating coronary artery disease |
CN110279662A (zh) * | 2019-06-05 | 2019-09-27 | 合肥合源药业有限公司 | 一种难溶性药物卡维地洛的固体分散体及制备方法和应用 |
US10772869B1 (en) | 2019-07-24 | 2020-09-15 | ECI Pharmaceuticals, LLC | Pharmaceutical compositions including carvedilol and methods of using the same |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2815926A1 (de) * | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US4053067A (en) * | 1973-06-25 | 1977-10-11 | Westinghouse Electric Corporation | Fuel transfer system for a nuclear reactor |
DE3319027A1 (de) * | 1983-05-26 | 1984-11-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten |
US4985464A (en) | 1984-05-23 | 1991-01-15 | Rudolf Happle | Drug compositions for local treatment of alopecia areata |
US5405863A (en) | 1992-12-01 | 1995-04-11 | Smithkline Beecham Corporation | Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds |
US5308862A (en) | 1993-03-05 | 1994-05-03 | Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 | Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation |
US5393772A (en) | 1993-11-24 | 1995-02-28 | Boehringer Mannheim Pharmaceuticals Corporation | Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation |
US5760069A (en) | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
US20010011099A1 (en) | 1995-05-30 | 2001-08-02 | Smithkline Beecham Corporation | Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds |
WO1998002157A1 (de) | 1996-07-13 | 1998-01-22 | Roche Diagnostics Gmbh | Topisch einsetzbare pharmazeutische formulierungen enthaltend als wirkstoff ein carbazolyl-(4)-oxy-propanolamin-derivat |
BR9711228A (pt) | 1996-08-23 | 2000-01-11 | Boeringer Mannheim Pharmaceuti | Método para a inibição da expressão de fas |
ZA979055B (en) | 1996-10-09 | 1999-05-10 | Boehringer Mannheim Pharm Corp | Method for inhibiting stress-activated protein kinases |
US6730326B2 (en) | 1997-07-22 | 2004-05-04 | Roche Diagnostics Gmbh | Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it |
EP0893440A1 (en) * | 1997-07-22 | 1999-01-27 | Roche Diagnostics GmbH | Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it |
GT199800126A (es) | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
ZA989365B (en) | 1997-10-15 | 1999-04-15 | Boehringer Mannheim Pharm Corp | Preparation for treating alzheimer's disease |
US20020054911A1 (en) | 2000-05-11 | 2002-05-09 | Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi | Novel oral dosage form for carvedilol |
US6541479B1 (en) | 1997-12-02 | 2003-04-01 | Massachusetts College Of Pharmacy | Calcium channel blockers |
US6852337B2 (en) | 1998-04-09 | 2005-02-08 | Roche Diagnostics Gmbh | Carvedilol-galenics |
DE69910188T2 (de) | 1998-04-09 | 2004-06-17 | Roche Diagnostics Gmbh | Arzneiformen enthaltend carvedilol |
DE19833119A1 (de) * | 1998-07-23 | 2000-01-27 | Roche Diagnostics Gmbh | Spritzfertige Injektionslösungen enthaltend Carvedilol |
US6664284B2 (en) | 1998-07-23 | 2003-12-16 | Roche Diagnostics Gmbh | Stabilized carvedilol injection solution |
PE20001302A1 (es) | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
JP2003514019A (ja) | 1999-11-15 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | カルベジロールメタンスルホン酸塩 |
US20020068740A1 (en) | 1999-12-07 | 2002-06-06 | Mylari Banavara L. | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications |
US20010036959A1 (en) * | 2000-04-03 | 2001-11-01 | Gabel Rolf Dieter | Carvedilol-hydrophilic solutions |
JP2003528914A (ja) | 2000-04-03 | 2003-09-30 | エフ.ホフマン−ラ ロシュ アーゲー | カルベジロールの濃縮溶液 |
WO2001078725A2 (en) | 2000-04-13 | 2001-10-25 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
DK174645B1 (da) * | 2000-05-18 | 2003-08-04 | Gea Farmaceutisk Fabrik As | Fremgangsmåde og mellemprodukter til fremstillingen af 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol og syreadditionssalte deraf |
JP2004501191A (ja) | 2000-06-28 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | カルベジロール |
US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
WO2002078692A1 (en) | 2001-04-02 | 2002-10-10 | Smithkline Beecham Corporation | Method of treatment |
IN191028B (no) | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
FI20011464A0 (fi) | 2001-07-04 | 2001-07-04 | Orion Corp | Yhdistelmäterapia sydämen vajaatoiminnan hoitoon |
ATE381924T1 (de) | 2001-09-21 | 2008-01-15 | Egalet As | Feste dispersionen mit kontrollierter freisetzung von carvedilol |
EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
RU2308449C2 (ru) | 2001-09-28 | 2007-10-20 | Ф.Хоффманн-Ля Рош Аг | Псевдополиморфные формы карведилола |
WO2003028718A1 (en) | 2001-10-01 | 2003-04-10 | Smithkline Beecham Corporation | Novel formulations of carvedilol |
WO2003028645A2 (en) | 2001-10-01 | 2003-04-10 | Smithkline Beecham Corporation | Novel compositions of carvedilol |
CA2462275A1 (en) | 2001-10-02 | 2003-04-10 | Smithkline Beecham Corporation | Novel composition of carvedilol |
US20040019096A1 (en) | 2001-10-23 | 2004-01-29 | Vlassios Andronis | Novel formulations of carvedilol |
EP1474133A4 (en) | 2002-01-15 | 2006-02-01 | Teva Pharma | SOLID CRYSTALLINE CARVEDILOL BODIES AND METHODS OF MAKING SAME |
JP2006500320A (ja) | 2002-04-30 | 2006-01-05 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール一クエン酸塩一水和物 |
BR0312102A (pt) * | 2002-06-27 | 2007-05-29 | Sb Pharmco Inc | sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento |
US20040152756A1 (en) | 2002-07-15 | 2004-08-05 | Wei Chen | Carvedilol polymorph |
EP1542728A4 (en) | 2002-07-22 | 2005-09-21 | Nanohybrid Co Ltd | HYBRID OF ITRACONAZOLE, CYCLOSPORINE OR CARVEDILOL WITH A LAYERED SILICATE AND PROCESS FOR PREPARING THE SAME |
ES2204303B2 (es) * | 2002-08-07 | 2004-12-16 | Laboratorios Vita, S.A. | Procedimiento para la obtencion de un compuesto farmaceuticamente activo. |
WO2004016249A1 (en) | 2002-08-14 | 2004-02-26 | Ranbaxy Laboratories Limited | Extended release matrix tablets |
AU2003275953A1 (en) | 2002-11-08 | 2004-06-07 | Egalet A/S | Controlled release carvedilol compositions |
AU2003288608A1 (en) | 2002-12-20 | 2004-07-14 | Ranbaxy Laboratories Limited | Controlled release, multiple unit drug delivery systems |
WO2005051325A2 (en) | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Carvedilol compositions methods of treatment and delivery |
JP2007512372A (ja) | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール塩、対応する組成物、送達および/または治療方法 |
US8734850B2 (en) * | 2003-11-25 | 2014-05-27 | Flamel Technologies | Oral medicinal product with modified release of at least one active principle in multimicrocapsular form |
-
2003
- 2003-06-27 BR BRPI0312102-0A patent/BR0312102A/pt not_active Application Discontinuation
- 2003-06-27 CN CN2013100984468A patent/CN103333099A/zh active Pending
- 2003-06-27 CN CN2013100984947A patent/CN103288714A/zh active Pending
- 2003-06-27 CN CN2013100986020A patent/CN103288715A/zh active Pending
- 2003-06-27 CN CN201010152481XA patent/CN101898995B/zh not_active Expired - Lifetime
- 2003-06-27 KR KR1020117028711A patent/KR20110134952A/ko not_active Application Discontinuation
- 2003-06-27 AU AU2003248746A patent/AU2003248746B2/en not_active Expired
- 2003-06-27 EA EA200500091A patent/EA008384B1/ru not_active IP Right Cessation
- 2003-06-27 NZ NZ537161A patent/NZ537161A/en not_active IP Right Cessation
- 2003-06-27 MX MXPA04012923A patent/MXPA04012923A/es active IP Right Grant
- 2003-06-27 KR KR1020137008295A patent/KR101468827B1/ko active IP Right Grant
- 2003-06-27 KR KR1020137033808A patent/KR20140006111A/ko not_active Application Discontinuation
- 2003-06-27 CA CA2492060A patent/CA2492060C/en not_active Expired - Lifetime
- 2003-06-27 EP EP03762176A patent/EP1534270A4/en not_active Ceased
- 2003-06-27 CN CN2013100984294A patent/CN103254114A/zh active Pending
- 2003-06-27 JP JP2004518025A patent/JP2005533823A/ja not_active Withdrawn
- 2003-06-27 WO PCT/US2003/020408 patent/WO2004002419A2/en active Application Filing
- 2003-06-27 CN CNA038202301A patent/CN1678305A/zh active Pending
- 2003-06-27 US US10/518,654 patent/US7268156B2/en not_active Expired - Lifetime
-
2004
- 2004-12-10 ZA ZA200410011A patent/ZA200410011B/xx unknown
- 2004-12-16 IL IL165814A patent/IL165814A/en not_active IP Right Cessation
-
2005
- 2005-01-25 NO NO20050427A patent/NO329710B1/no not_active IP Right Cessation
-
2007
- 2007-06-25 US US11/767,566 patent/US20070259940A1/en not_active Abandoned
- 2007-06-25 US US11/767,581 patent/US7759384B2/en not_active Expired - Lifetime
- 2007-06-25 US US11/767,586 patent/US7902378B2/en not_active Expired - Lifetime
- 2007-06-25 US US11/767,573 patent/US7626041B2/en not_active Expired - Lifetime
- 2007-06-25 US US11/767,578 patent/US7893100B2/en active Active
-
2010
- 2010-12-17 JP JP2010282048A patent/JP5422545B2/ja not_active Expired - Lifetime
-
2013
- 2013-08-02 JP JP2013161656A patent/JP2013241450A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20050427L (no) | Carvedilolfosfatsalter og/eller solvater derav, tilsvarende preparater og/eller behandlingsfremgangsmater | |
NO20053817D0 (no) | Preparater og fremgangsmater for antiviral kombinasjonsterapi. | |
IS7701A (is) | Arípíprazól samsett lyfjaform og aðferð | |
DK1511734T3 (da) | Forbindelser, præparater og fremgangsmåder | |
NO20011964L (no) | Brönnbehandlingsfluider og fremgangsmåter for anvendelse derav | |
NO20043839L (no) | Havbunnsbasert intervensjonssystem, fremgangsmate for og komponeter i dette | |
NO20052855D0 (no) | Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav. | |
NO20053593D0 (no) | Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi | |
EP1571910A4 (en) | CYTOTHERAPEUTIC AGENTS, CYTOTHERAPEUTIC UNITS AND METHODS OF TREATMENT IN WHICH THEY INTERVENE | |
NO20052462D0 (no) | Kombinasjonsterapi under anvendelse av 1-aminosykloheksanderivater og acetyl-cholinesteraseinhibitorer | |
IS8071A (is) | Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum | |
NO20033301D0 (no) | Fremgangsmåte og system for simulering av kirurgiske prosedyrer | |
DE60328977D1 (de) | System zur positionierung von implantierbaren medizinischen vorrichtungen in den koronarvenen | |
IS7798A (is) | Efnasambönd, lyfjablöndur og aðferðir | |
DK1503788T3 (da) | Behandling af alpha-galactosidase A-deficiens | |
DK1372650T3 (da) | Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat | |
NO20042084L (no) | 6-hydroksyisoflavoner, derivater og legemidler som omfatter disse | |
DK1513835T3 (da) | Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf | |
DK1228028T3 (da) | Hydroxyicosatetraenoatsalte, præparater og fremgangsmåder til anvendelse til behandling af öjentörhedslidelser | |
NO20031552L (no) | Fremgangsmate og system for handtering av web-sesjoner | |
IS7577A (is) | Arómatísk súlfón og læknisfræðileg notkun þeirra | |
DK1417189T3 (da) | Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf | |
ITRM20030236A1 (it) | Procedimento ed apparecchio per la simulazione | |
DK1525193T3 (da) | Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse | |
DK1556382T3 (da) | 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |